The American Joint Commission on Cancer (AJCC) tumor node metastasis (TNM) staging system is the "language of cancer" by which physicians communicate about the disease process.[@CR1] Staging ensures an objective, reproducible classification of the extent of disease and is our most important determinant of treatment recommendations. For research purposes, clinical trials depend on staging for appropriate patient stratification upon which accurate measurement of the treatment effect under study can be performed. Perhaps most importantly to the patient, staging is our best tool to provide prognostic information in our effort to manage patient expectations in the context of a suggested treatment plan.

Current staging for pancreatic cancer is based on the 6th edition of the *AJCC Cancer Staging Manual,* published in 2002 (Table [1](#Tab1){ref-type="table"}).[@CR2] This update has been validated for pancreatic cancer using the National Cancer Database (NCDB) and shown to have good survival discrimination between stages.[@CR3] However, because survival within a particular stage is highly variable, the Memorial Sloan Kettering Cancer Center (MSKCC) developed a nomogram to better predict the likelihood of disease-specific survival after initial resection for pancreatic carcinoma.[@CR4] This nomogram incorporates additional factors into the predictive model not included in traditional TNM staging, one of which is the degree of differentiation or grade of the tumor. Predictions by the nomogram discriminated better than AJCC stage, suggesting that incorporation of additional variables would improve accuracy. This nomogram was independently validated by the group at Massachusetts General Hospital on a cohort of 424 patients.[@CR5]Table 1American Joint Committee on Cancer (AJCC) 6th edition TNM staging system for pancreatic cancerT stage (primary tumor) TXPrimary tumor cannot be assessed T0No evidence of primary tumor TisCarcinoma in situ T1Tumor limited to pancreas and ≤2 cm T2Tumor limited to pancreas and \>2 cm T3Tumor extends beyond pancreas T4Tumor extends beyond pancreas and involves the celiac axis or superior mesenteric artery (unresectable)N stage (regional lymph nodes) NXRegional nodes cannot be assessed N0No regional lymph node metastasis N1Regional lymph node metastasisM stage (distant sites) MXDistant metastasis cannot be assessed M1Distant metastasisStage grouping Stage 0TisN0M0Localized Stage  IAT1N0M0Localized Stage IBT2N0M0Localized Stage IIAT3N0M0Locally invasive Stage IIBT1--3N1M0Locally invasive Stage IIIT4Any NM0Unresectable Stage IVAny TAny NM1Distant metastasis

Several other multivariate analyses have shown that tumor grade is an important prognostic indicator after resection of pancreatic cancer.[@CR6]--[@CR11] Grade is a measure of the degree of differentiation of the tumor. Differentiation refers to the morphologic and functional resemblance between a tumor cell and a normal cell of the same tissue. Malignant neoplasms range from well differentiated (low grade) to undifferentiated (high grade); in general, the more undifferentiated the tumor, the more aggressive the malignant biology.[@CR12] For pancreatic adenocarcinomas, histologic grade is based on the extent of glandular differentiation. If \>95% of the tumor is composed of glands then it is classified as being well differentiated, 50%--95% is moderately differentiated, and \<50% is poorly differentiated.[@CR2]

The aim of this study was to use a population-based database providing significant power to assess the impact of tumor grade on prognosis after resection for pancreatic cancer. We hypothesized that some of the variability in survival within the same AJCC stage might be the result of differences in tumor grade. Our goal was to assess the significance of tumor grade as a predictive factor independent of known adverse predictors of survival. Furthermore, we sought to develop a novel staging system that would incorporate grade into the existing TMN system in hopes of providing improved staging that is more reflective of the underlying tumor biology and associated survival.

Methods {#Sec1}
=======

SEER Database {#Sec2}
-------------

The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) tumor registry database was used for this study. SEER contains more than 3 million cases from 17 geographic sites, covering approximately 26% of the U.S. population. The database was designed to reflect the overall characteristics of the U.S. population and is regarded as a model population-based tumor registry. Quality control is an important component of the SEER program; the current standard for accuracy of the data in the registry is an error rate of less than 5%.[@CR13] SEER Program registries routinely collect data on patient demographics (e.g., age, sex), primary tumor characteristics (e.g., size, extent, grade), nodal staging (number of nodes examined, number of positive nodes), surgery performed (pancreaticoduodenectomy vs distal pancreatectomy), vital status, and survival. Although information on radiation therapy is recorded, no information on chemotherapy is reported. The November 2007 update was used for this study, providing information from 1973 to 2005.[@CR14] As a population-based study with no patient identifiers involved, our study was exempt from institutional research board review.

Case Selection {#Sec3}
--------------

The study period was from 1991 to 2005. The ICD-10 histology codes 8000, 8010, 8020, 8021, 8140, 8141, and 8500 were used to identify all patients with a diagnosis of adenocarcinoma of the pancreas. Patients who did not undergo cancer-directed surgery were excluded from the analysis. Also excluded were patients with no histological confirmation of the diagnosis and cases identified from autopsy reports only. Although no specific field for AJCC stage in pancreatic cancer is provided in the SEER database, the information to accurately stage patients is present in other data fields. Using extent of disease (EOD) data fields, we were able to determine stage according to the 6th edition of the *AJCC Staging Manual*, as our group and others have done so previously.[@CR15],[@CR16] Complete TNM data were available for 7627 out of 8082 patients (94.4%) using the EOD codes. In the SEER database, tumor grade is coded as 1 (well differentiated), 2 (moderately differentiated), 3 (poorly differentiated), or 4 (undifferentiated). Tumor grade was recorded for 7086 out of 8082 patients (88%).

Statistical Analysis {#Sec4}
--------------------

Kaplan--Meier curves and log-rank tests were used to identify differences in overall survival, defined as duration of survival after initial resection of pancreatic carcinoma. Predictors of survival after surgical resection for the entire cohort were identified by Cox regression analysis using proportional hazards modeling. Variables included in the model were age, sex, tumor size, lymph node status, and tumor grade. Only patients with complete data were included in the multivariate analysis. Thus, 5935 of 8082 patients were eligible for inclusion in the multivariate analysis. A separate multivariate analysis was performed to identify predictors of survival for stages I, IIA, IIB, III, and IV individually. Stages IA and IB were combined together to ensure adequate numbers for analysis. For stages I, IIA, and IIB variables in the model were age, sex, tumor size, and tumor grade only. Lymph node status was not included because by definition all patients in stages I and IIA are node negative and patients in stage IIB are node positive. In our study, grade was redefined as a dichotomous, categorical variable: tumor grades 1 (well differentiated) and 2 (moderately differentiated) were combined into a "low-grade" group and tumor grades 3 (poorly differentiated) and 4 (undifferentiated) into a "high-grade" group. Categorical variables were compared between low-grade and high-grade groups using chi-square analysis. Differences between continuous variables were determined using *t* test. Significance levels were set at *P* \< .05 and confidence intervals were 95%. All tests were two-tailed. Predictors of high tumor grade were identified using logistic regression analysis. Factors included in the model were sex, tumor size, lymph node status, and presence of extrapancreatic invasion. Patients with incomplete data were excluded from regression analysis. All statistical analysis was performed using SPSS 16.0 statistical software (SPSS Inc., Chicago IL).

Results {#Sec5}
=======

Our study population consisted of 8082 patients who underwent resection of pancreatic adenocarcinoma. Demographic, tumor, and treatment characteristics of the entire cohort as well as low-grade and high-grade groups are detailed in Table [2](#Tab2){ref-type="table"}. A total of 996 (12%) patients did not have tumor grade recorded. Significant differences were seen between the high-grade and low-grade cohort with regard to sex, tumor size, lymph node involvement, number of positive nodes, AJCC stage, and reception of radiation treatment.Table 2Demographic, tumor and treatment characteristicsDemographicsAll patients (*n* = 8082)Low-grade tumor^a^ (*n* = 4491)High-grade tumor^a^ (*n* = 2595)*P* valueSex (%).009 Male50.449.052.3Age (y)NS Mean ± SD65.2 ± 11.065.2 ± 10.865.3 ± 10.9 Median66.066.366.5Race (%)NS White83.182.984.2 Black9.99.99.2 Other6.87.36.6Tumor location (%)NS Head85.685.785.4 Body5.15.24.9 Tail9.49.19.7Type of surgery (%)NS Whipple procedure82.482.282.7 Distal pancreatectomy9.39.49.2 Total pancreatectomy8.38.48.0Tumor size (cm)\<.001 Mean ± SD3.5 ± 1.93.4 ± 1.83.7 ± 2.1 Median3.13.03.4 Lymph node status (%)\<.001 Positive60.357.964.6AJCC state (%)\<.001 IA4.35.22.7 IB8.18.77 IIA24.625.722.7 IIB49.548.651 III6.86.57.4 IV6.75.29.1Number of nodes examinedNS Mean ± SD9.8 ± 8.09.8 ± 8.09.8 ± 8.0 Median8.08.08.0Number of positive nodes.006 Mean ± SD2.9 ± 2.62.9 ± 2.53.1 ± 2.7 Median2.12.02.6Radiation (%).001 Yes42.744.240.2Percentages may not add up to 100 due to rounding*AJCC* American Joint Committee on Cancer^a^Low grade included grades 1 and 2; high grade included grades 3 and 4. Excluded from these 2 columns were 996 patients for whom data were unavailable

For each AJCC stage classification, survival was significantly worse with high-grade (3 or 4) versus low-grade (1 or 2) tumors (Fig. [1](#Fig1){ref-type="fig"}). Multivariate analysis of the entire cohort identified the following independent predictors of adverse outcome: increasing age, male sex, tumor size \>2 cm, lymph node positivity, and high tumor grade. Importantly, the hazard ratio (HR) associated with high tumor grade (HR = 1.4) was of a similar magnitude and significance when compared with tumor size (HR = 1.37) and node status (HR = 1.38). When each stage was analyzed separately, high tumor grade remained an independent predictor of survival across all stages (Table [3](#Tab3){ref-type="table"}). Interestingly, in the stage IV patients who underwent a resection, grade was the only independent prognostic variable (HR = 1.58).Fig. 1Kaplan-Meier survival curves stratified by grade for patients with stage I (**a**), stage IIA (**b**), stage IIB (**c**), stage III (**d**), and stage IV (**e**) diseaseTable 3Cox regression analysesPatient groupHazard ratio (95% CI)*P* value**Entire cohort (*n* = 5935)** Age (y)  \<55^a^1.00  56--651.10 (1.01--1.21).037  66--751.26 (1.16--1.37)\<.001  \>751.48 (1.35--1.64)\<.001 Sex  Female^a^1.00  Male1.07 (1.00--1.13).035 Node status  Negative^a^1.00  Positive1.38 (1.30--1.47)\<.001 Tumor size (cm)  \<2^a^1.00  \>21.37 (1.27--1.48)\<.001  Tumor grade  Low^a^1.00  High1.40 (1.31--1.48)\<.001**Stage I (*n* = 845)** Age (y)  \<55^a^1.00  56--651.21 (.92--1.58).18  66--751.50 (1.17--1.91).001  \>751.72 (1.31--2.26)\<.001 Tumor size (cm)  \<2^a^1.00  \>21.33 (1.11--1.60).002  Tumor grade  Low^a^1.00  High1.28 (1.07--1.54).007**Stage IIA (*n* = 1501)** Tumor size (cm)  \<2^a^1.00  \>21.27 (1.10--1.47).001 Tumor grade  Low^a^1.00  High1.43 (1.26--1.61)\<.001**Stage IIB (*n* = 3140)** Age (y)  \<55^a^1.00  56--651.04 (.92--1.17).543  66--751.23 (1.10--1.38)\<.001  \>751.54 (1.34--1.76)\<.001 Tumor size (cm)  \<2^a^1.00  \>21.37 (1.23--1.54)\<.001 Tumor grade  Low^a^1.00  High1.38 (1.27--1.50)\<.001**Stage III (*n* = 384)** Age (y)  \<55^a^1.00  56--651.19 (.86--1.64).29  66--751.37 (1.00--1.86).047  \>751.81 (1.28--2.57).001 Tumor grade  Low^a^1.00  High1.28 (1.02--1.59).032**Stage IV (*n* = 270)** Tumor grade  Low^a^1.00  High1.58 (1.21--2.05).001*n* = patients with all variables available for regression analysis^a^Referent

Predictors of high tumor grade were tumor size \>2 cm (odds ratio \[OR\] 1.39, 95% confidence interval \[95% CI\] 1.18--1.65, *P* \< .001), positive lymph nodes (OR 1.24, 95% CI 1.08--1.42, *P* = .002), and peripancreatic invasion (OR 1.20, 95% CI 1.03--1.41, *P* = .02). Female sex was a protective factor (OR .85, 95% CI .74--.97, *P* = .013).

Tumor grade (G) was incorporated into AJCC (TNM) staging system to generate a novel TNMG staging system for 6862 out of 8082 patients (84.9%). This TNMG staging differs from the AJCC staging by advancing a patient to the next higher stage level in the presence of high tumor grade (Table [4](#Tab4){ref-type="table"}). For instance a high-grade stage IIA tumor in the TNM staging system would now be a stage IIB tumor in the novel TNMG system. By restaging patients in this manner, the impact of grade on survival can be realized, as demonstrated by a 2-month improvement in median survival of stage IIA patients simply by advancing patients with high-grade tumors and associated worse survival into stage IIB. Excellent discrimination in overall survival between stages is also seen in this novel TNMG staging classification and appears to be durable throughout all time points as the curves remain separate through 5 years (Fig. [2](#Fig2){ref-type="fig"}).Table 4Restaging according to TNMG classificationFig. 2Kaplan-Meier survival curves based on TNMG classification showing excellent discrimination between stages

Discussion {#Sec6}
==========

The aim of this study was to use a population-based tumor registry to assess the impact of tumor grade on prognosis after surgical resection for pancreatic cancer. We believe that the variability in survival within each AJCC stage may be attributed to factors not currently incorporated into the staging system, one of which is tumor grade. Our data show that within each AJCC stage, high tumor grade is an independent and significant predictor of adverse outcome. When patients are restaged with grade incorporated into a novel TNMG staging system, excellent discrimination in survival between stages is seen.

The largest series on surgical resection for pancreatic cancer in the literature includes 1423 patients who underwent pancreaticoduodenectomies at the Johns Hopkins Medical Institutions.[@CR8] Among other variables, the authors report histologic grade as an independent predictor of survival on multivariate analysis, with a hazard ratio of 1.6. Other single-institution studies have confirmed this on both univariate and multivariate analysis with a hazard ratio that varies between 1.14 and 2.56.[@CR9]--[@CR11] Our population-based study reports a hazard ratio of 1.40 for high tumor grade, which falls well within the range reported in the literature.

Largely in concert with published studies, we found tumor size \>2 cm, lymph node positivity, age, and male sex as adverse prognostic factors for the entire cohort. Tumor size and lymph node involvement are well-known prognostic indicators for pancreatic cancer and, along with distant metastases, form the trifecta of the current TNM-based AJCC staging for pancreatic cancer. Many studies have shown that patients with a tumor larger than 2 cm or lymph node involvement have a significantly lower median and 5-year survival.[@CR6]--[@CR11],[@CR17]--[@CR21] Other studies show that patients who are elderly have a worse outcome than younger patients after surgical resection of pancreatic cancer.[@CR22],[@CR23] Similarly, we also show that males have poorer survival than females, which may be related to the presence of lower-grade tumors in females as demonstrated by our data.[@CR4],[@CR5]

Especially pertinent to the context of our study are clinical trials for adjuvant treatment of pancreatic cancer. In the CONKO-001 trial of adjuvant gemcitabine versus observation after resection of pancreatic cancer, the median overall survival was 22.8 months in the gemcitabine group and 20.2 months in the observation group (*P* = .005).[@CR24] Similarly in the ESPAC-1 trial, adjuvant chemotherapy with 5-fluorouracil/leucovorin had a statistically significant benefit over observation with respect to median survival (20.1 vs 15.5 months, *P* = .009).[@CR25] Lastly, the RTOG 97--04 trial randomized patients to chemoradiotherapy using 5FU versus chemoradiotherapy with gemcitabine. The results demonstrated a 3.7-month difference in median survival in favor of the chemoradiotherapy/gemcitabine regimen.[@CR26] In none of these trials were patients stratified by grade. Given the magnitude of difference in median survival in these adjuvant trials and the potential impact of grade on survival, it is feasible that stratifying upon grade could alter the median survival difference and possibly the significance of these trial results. We have shown that stratifying AJCC stage IIB resected tumors (node positive) by grade demonstrates a 4-month improvement in median survival for node-positive, low-grade tumors compared with node-positive, high-grade tumors, which is comparable to the difference in median survival seen in the trial results quoted previously. Some may argue that randomization would automatically adjust for this factor; however, given the degree to which most trials in pancreatic cancer are underpowered, the risk for bias resulting from inaccurate stratification becomes much greater with such an influential factor such as grade. This study shows that high tumor grade (HR 1.40) has a larger impact on survival than both node positivity (HR 1.38) and tumor size \>2 cm (HR 1.37), both of which are part of the current AJCC staging system and are used to risk stratify patients routinely.

Our data make a strong case for inclusion of tumor grade into current staging for pancreatic cancer; therefore, we proposed a novel TNMG staging system. With the addition of grade to the current AJCC staging system, we are better able to tease out the "best case scenario" patients in stage IA (low-grade tumors, \<2 cm, node negative and localized to the pancreas) and show an improvement in median survival of 3 months compared with stage IA in TNM staging (\<2 cm, node negative and localized). We can also identify the "bad actors" in stage IIA (high-grade tumors, node negative, and locally invasive) and move them to stage IIB in TNMG staging; again an improvement in median survival of 2 months compared with stage IIA in TNM staging. Furthermore, dividing stage IV patients into stage IVA (low grade with median survival 8 months) and stage IVB (high grade with median survival 5 months) provides better risk stratification in the very patient population most likely to enroll in future clinical trials to evaluate potential new therapies. Moreover, in support of our contention that discrimination in survival is improved with TNMG staging, the overall "spread" in median survival for TNMG staging is 25 months (range 5--30 months), which compares with 21 months with TNM staging (range 6--27 months).

Importantly, we demonstrate that not only does addition of tumor grade makes sense given its significant and independent impact on survival, but it can be added to the existing TNM staging system in a relatively simple manner. In other words, the novel TNMG staging system proposed does not create a more complex staging system but rather builds upon the existing AJCC staging system with improved reflection of the underlying biology and associated impact on survival. This is not a trivial point as more complex staging systems such as the previously mentioned nomograms have not been widely adopted in spite of improved prognostication.

Tumor grade is already part of staging for prostate cancer, sarcomas, and certain bone tumors. For a prognostic factor to be included in the staging system, it must explain some of the heterogeneity associated with the expected course and outcome of a disease.[@CR1] Our analysis shows that tumor grade in pancreatic cancer meets this criterion. Pathology studies of pancreatic cancer have examined a scoring system based on grade, similar to Gleason score for prostate cancer, and have shown good predictive ability as well as reproducibility.[@CR27] Similarly Eltoum et al. devised a cytologic grading system for biopsy specimens obtained by endoscopic ultrasound-guided fine-needle aspiration to predict survival in patients with pancreatic adenocarcinoma.[@CR28]

The use of population-based data has several inherent limitations. Even though the database is checked regularly for discrepancy and reportedly has 95% accuracy, the possibility of coding errors remains. Furthermore, we cannot account for variability among SEER regions in pathology protocols used to assess tumor grade, as well as interobserver variability among pathologists. As mentioned previously, no information on chemotherapy is provided in the database so we were unable to assess the impact of adjuvant therapy. Additionally, margin status is not recorded in SEER. Nevertheless, the use of a population database enables us to study a large contemporary sample of patients and make significant statistical conclusions relevant to the general population, which is not possible in single-institution studies.

In this study we use the SEER cancer registry to show that tumor grade is a significant and independent prognostic factor for survival after resection of pancreatic adenocarcinoma. In fact, high tumor grade has a greater impact on survival in pancreatic cancer than known poor prognostic factors such as lymph node positivity and tumor size, which form the basis of our current staging system. We believe inclusion of tumor grade into AJCC staging for pancreatic cancer would enhance the current system and provide better survival prognostication reflective of the aggressive biology associated with high-grade tumors. These findings may have implications for adjuvant therapy decision making as well as risk stratification of patients entering future clinical trials.
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